• Egil Røsjø, Kjell-Morten Myhr, Kristin I Løken-Amsrud, Søren J Bakke, Antonie G Beiske, Kristian S Bjerve, Harald Hovdal, Finn Lilleås, Rune Midgard, Tom Pedersen, Šaltytė Benth Jūratė J Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Helse Sør-Øst Health Services Research Centre, Akershus University Hospital, Løre, Øivind Torkildsen, Stig Wergeland, Annika E Michelsen, Pål Aukrust, Thor Ueland, and Trygve Holmøy.
• Department of Neurology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: egil.rorvik.rosjo@ahus.no.
• J. Neuroimmunol. 2015 Mar 15; 280: 21-8.

AbstractTo explore if vitamin D modulates interferon-β1a treatment effects in relapsing-remitting multiple sclerosis, we examined relationships between serum vitamin D and magnetic resonance imaging (MRI) activity and ten systemic inflammation markers in 88 patients, before and during treatment. Odds ratios for all MRI parameters were negatively associated with vitamin D levels before therapy, but converged to equally low values irrespective of vitamin D status during treatment. During therapy, similar alterations of MRI activity and inflammation markers were found across patients categorized by mean vitamin D values. This suggests that vitamin D status has no major influence on interferon-β1a treatment effects. Copyright © 2015 Elsevier B.V. All rights reserved.

28 keywords...

hide…